Immunis is a private biotechnology company researching and developing secretome products to address age-driven immune dysfunction. Our investigational secretome product, IMMUNA, leverages our leading-edge capabilities in cell culture to deliver a product of all natural, all human immune modulators in their natural relative concentrations. There is preclinical data supporting that IMMUNA benefits muscle regeneration and metabolism. Immunis is currently testing the effects of IMMUNA in a Phase 1/2a clinical trial for age-related muscle atrophy.